Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab

MLA

Sae-Won Han, et al. “Quantitative Measurement of HER2 Levels by Multiplexed Mass Spectrometry to Predict Survival in Gastric Cancer Patients Treated with Trastuzumab.” Journal of Clinical Oncology, vol. 33, May 2015, p. 4050. EBSCOhost, https://doi.org/10.1200/jco.2015.33.15_suppl.4050.

APA

Sae-Won Han, Jon Burrows, Adele Blackler, William Arthur Hoos, Fabiola Cecchi, Do-Youn Oh, Woo Ho Kim, Sheeno Thyparambil, Seock-Ah Im, Tae-You Kim, Todd Hembrough, Chan Young Ock, Yung-Jue Bang, Tae Yong Kim, Kyung-Hun Lee, Wei-Li Liao, & Eunkyung An. (2015). Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. Journal of Clinical Oncology, 33, 4050. https://doi.org/10.1200/jco.2015.33.15_suppl.4050

Chicago

Sae-Won Han, Jon Burrows, Adele Blackler, William Arthur Hoos, Fabiola Cecchi, Do-Youn Oh, Woo Ho Kim, et al. 2015. “Quantitative Measurement of HER2 Levels by Multiplexed Mass Spectrometry to Predict Survival in Gastric Cancer Patients Treated with Trastuzumab.” Journal of Clinical Oncology 33 (May): 4050. doi:10.1200/jco.2015.33.15_suppl.4050.